Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies (Eye, (2023), 37, 6, (1242-1248), 10.1038/s41433-022-02092-5)

David R. Lally*, Anat Loewenstein, Jennifer J. Arnold, Yit C. Yang, Kinfemichael Gedif, Catherine Best, Hersh Patel, Ramin Tadayoni, Jeffrey S. Heier

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

With

Original languageEnglish
Pages (from-to)1748
Number of pages1
JournalEye
Volume37
Issue number8
DOIs
StatePublished - Jun 2023

Fingerprint

Dive into the research topics of 'Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies (Eye, (2023), 37, 6, (1242-1248), 10.1038/s41433-022-02092-5)'. Together they form a unique fingerprint.

Cite this